全文获取类型
收费全文 | 22382篇 |
免费 | 1547篇 |
国内免费 | 52篇 |
专业分类
耳鼻咽喉 | 181篇 |
儿科学 | 662篇 |
妇产科学 | 637篇 |
基础医学 | 3413篇 |
口腔科学 | 723篇 |
临床医学 | 2745篇 |
内科学 | 3907篇 |
皮肤病学 | 561篇 |
神经病学 | 2126篇 |
特种医学 | 479篇 |
外国民族医学 | 2篇 |
外科学 | 2262篇 |
综合类 | 149篇 |
一般理论 | 41篇 |
预防医学 | 2294篇 |
眼科学 | 321篇 |
药学 | 1723篇 |
中国医学 | 47篇 |
肿瘤学 | 1708篇 |
出版年
2023年 | 173篇 |
2022年 | 265篇 |
2021年 | 665篇 |
2020年 | 371篇 |
2019年 | 633篇 |
2018年 | 664篇 |
2017年 | 481篇 |
2016年 | 581篇 |
2015年 | 550篇 |
2014年 | 805篇 |
2013年 | 1085篇 |
2012年 | 1509篇 |
2011年 | 1581篇 |
2010年 | 859篇 |
2009年 | 748篇 |
2008年 | 1256篇 |
2007年 | 1247篇 |
2006年 | 1250篇 |
2005年 | 1184篇 |
2004年 | 1024篇 |
2003年 | 894篇 |
2002年 | 887篇 |
2001年 | 330篇 |
2000年 | 349篇 |
1999年 | 335篇 |
1998年 | 193篇 |
1997年 | 167篇 |
1996年 | 131篇 |
1995年 | 139篇 |
1994年 | 135篇 |
1993年 | 117篇 |
1992年 | 231篇 |
1991年 | 253篇 |
1990年 | 223篇 |
1989年 | 217篇 |
1988年 | 217篇 |
1987年 | 206篇 |
1986年 | 207篇 |
1985年 | 209篇 |
1984年 | 136篇 |
1983年 | 146篇 |
1982年 | 106篇 |
1981年 | 111篇 |
1980年 | 91篇 |
1979年 | 123篇 |
1978年 | 109篇 |
1977年 | 104篇 |
1976年 | 73篇 |
1975年 | 68篇 |
1974年 | 75篇 |
排序方式: 共有10000条查询结果,搜索用时 562 毫秒
1.
Andres Eduardo Campuzano-García Bertha Torres-Alvarez Diana Hernández-Blanco 《Journal of cosmetic and laser therapy》2015,17(4):213-215
Hailey–Hailey disease (HHD), also known as benign familial pemphigus, is an autosomal dominant skin condition that affects the adhesion of epidermal keratinocytes. Although the initial manifestation of flaccid vesicles on erythematous or normal skin in flexure sites frequently goes unnoticed, large, macerated, exudative plaques of superficial erosions with crusting are observed at the time of diagnosis. There is no specific treatment for HHD, and most cases are symptomatically supported. However, infrared laser ablation has been somewhat helpful. We present a case successfully treated with fractional CO2 laser showing a long-term favourable outcome and no adverse effects. Thus, this modality could be an alternative to full ablation for this condition. 相似文献
2.
3.
4.
5.
6.
Ana M. Gómez Angelica Imitola Diana Henao Maira García-Jaramillo Marga Giménez Clara Viñals Bruno Grassi Mariana Torres Isabella Zuluaga Oscar Mauricio Muñoz Martin Rondón Fabián León-Vargas Ignacio Conget 《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2021,15(1):267-272
Background and aimsDespite using sensor-augmented pump therapy (SAPT) with predictive low-glucose management (PLGM), hypoglycemia is still an issue in patients with type 1 Diabetes (T1D). Our aim was to determine factors associated with clinically significant hypoglycemia (<54 mg/dl) in persons with T1D treated with PLGM-SAPT.Methodology: This is a multicentric prospective real-life study performed in Colombia, Chile and Spain. Patients with T1D treated with PLGM-SAPT, using sensor ≥70% of time, were included. Data regarding pump and sensor use patterns and carbohydrate intake from 28 consecutive days were collected. A bivariate and multivariate Poisson regression analysis was carried out, to evaluate the association between the number of events of <54 mg/dl with the clinical variables and patterns of sensor and pump use.Results188 subjects were included (41 ± 13.8 years-old, 23 ± 12 years disease duration, A1c 7.2% ± 0.9). The median of events <54 mg/dl was four events/patient/month (IQR 1–10), 77% of these events occurred during day time. Multivariate analysis showed that the number of events of hypoglycemia were higher in patients with previous severe hypoglycemia (IRR1.38; 95% CI 1.19–1.61; p < 0.001), high glycemic variability defined as Coefficient of Variation (CV%) > 36% (IRR 2.09; 95%CI 1.79–2.45; p < 0.001) and hypoglycemia unawareness. A protector effect was identified for adequate sensor calibration (IRR 0.77; 95%CI 0.66–0.90; p:0.001), and the use of bolus wizard >60% (IRR 0.74; 95%CI 0.58–0.95; p:0.017).ConclusionIn spite of using advanced SAPT, clinically significant hypoglycemia is still a non-negligible risk. Only the identification and intervention of modifiable factors could help to prevent and reduce hypoglycemia in clinical practice. 相似文献
7.
8.
María Cabrerizo Gloria Trallero María José Pena Amaia Cilla Gregoria Megias Carmen Mu?oz-Almagro Eva Del Amo Diana Roda Ana Isabel Mensalvas Antonio Moreno-Docón Juan García-Costa Nuria Rabella Manuel Ome?aca María Pilar Romero Sara Sanbonmatsu-Gámez Mercedes Pérez-Ruiz María José Santos-Mu?oz Cristina Calvo And the study group of “Enterovirus parechovirus infections in children under ?years-old Spain” PI- 《European journal of pediatrics》2015,174(11):1511-1516
9.
Marie Warrer Petersen Tine Sylvest Meyhoff Marie Helleberg Maj-Brit Nørregaard Kjær Anders Granholm Carl Johan Steensen Hjortsø Thomas Steen Jensen Morten Hylander Møller Peter Buhl Hjortrup Mik Wetterslev Gitte Kingo Vesterlund Lene Russell Vibeke Lind Jørgensen Klaus Tjelle Thomas Benfield Charlotte Suppli Ulrik Anne Sofie Andreasen Thomas Mohr Morten H. Bestle Lone Musaeus Poulsen Mette Friberg Hitz Thomas Hildebrandt Lene Surland Knudsen Anders Møller Christoffer Grant Sølling Anne Craveiro Brøchner Bodil Steen Rasmussen Henrik Nielsen Steffen Christensen Thomas Strøm Maria Cronhjort Rebecka Rubenson Wahlin Stephan Jakob Luca Cioccari Balasubramanian Venkatesh Naomi Hammond Vivekanand Jha Sheila Nainan Myatra Christian Gluud Theis Lange Anders Perner 《Acta anaesthesiologica Scandinavica》2020,64(9):1365-1375
Introduction
Severe acute respiratory syndrome coronavirus-2 has caused a pandemic of coronavirus disease (COVID-19) with many patients developing hypoxic respiratory failure. Corticosteroids reduce the time on mechanical ventilation, length of stay in the intensive care unit and potentially also mortality in similar patient populations. However, corticosteroids have undesirable effects, including longer time to viral clearance. Clinical equipoise on the use of corticosteroids for COVID-19 exists.Methods
The COVID STEROID trial is an international, randomised, stratified, blinded clinical trial. We will allocate 1000 adult patients with COVID-19 receiving ≥10 L/min of oxygen or on mechanical ventilation to intravenous hydrocortisone 200 mg daily vs placebo (0.9% saline) for 7 days. The primary outcome is days alive without life support (ie mechanical ventilation, circulatory support, and renal replacement therapy) at day 28. Secondary outcomes are serious adverse reactions at day 14; days alive without life support at day 90; days alive and out of hospital at day 90; all-cause mortality at day 28, day 90, and 1 year; and health-related quality of life at 1 year. We will conduct the statistical analyses according to this protocol, including interim analyses for every 250 patients followed for 28 days. The primary outcome will be compared using the Kryger Jensen and Lange test in the intention to treat population and reported as differences in means and medians with 95% confidence intervals.Discussion
The COVID STEROID trial will provide important evidence to guide the use of corticosteroids in COVID-19 and severe hypoxia.10.
Toneva Diana H. Nikolova Silviya Y. Tasheva-Terzieva Elena D. Zlatareva Dora K. Lazarov Nikolai E. 《International journal of legal medicine》2022,136(6):1851-1863
International Journal of Legal Medicine - Sex identification is a primary step in forensic analysis of skeletal remains. The accuracy of sex estimation methods greatly depends on the sexual... 相似文献